Andrea Haller, MD
Neurology · Fort Wayne, INNPI 1407853146
Payments from drug & device makers
Across 882 payments — averaging $899.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$262K
- Takeda Pharmaceuticals U.S.A., Inc.$146K
- Eli Lilly$142K
- Biohaven Pharmaceuticals, Inc.$87K
- Amgen$51K
- Lilly USA, LLC$39K
- plus $66K from 26 others
Across 5 payments — averaging $3569.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$18K
What the payments were for
- Consulting fees$11,6385%
- Speaking & faculty fees$208,39686%
- Travel & lodging$7,5823%
- Food & beverage$14,5166%
- Education$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 410 | $261,696 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $146,128 |
| Eli Lilly | 31 | $141,981 |
| Biohaven Pharmaceuticals, Inc. | 73 | $86,964 |
| Amgen | 7 | $51,212 |
| Lilly USA, LLC | 133 | $39,272 |
| Biohaven Pharmaceutical Holding Company Ltd. | 57 | $22,617 |
| Pfizer | 14 | $19,359 |
| Axsome Therapeutics, Inc. | 19 | $19,248 |
| Inspire Medical Systems, Inc. | 69 | $2,630 |
| H. Lundbeck A S | 3 | $947 |
| Teva Pharmaceuticals USA, Inc. | 2 | $151 |
| ZOLL Respicardia, Inc. | 1 | $136 |
| Livanova USA, Inc. | 5 | $127 |
| Novartis | 7 | $117 |
| SK Life Science, Inc. | 2 | $76 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Grifols USA, LLC | 2 | $40 |
| Biogen | 2 | $36 |
| EMD Serono, Inc. | 2 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Lundbeck LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Argenx US, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| GE HealthCare | 1 | $17 |
| GSK | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Krystal Biotech Inc | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$116,263
- QULIPTA$36,000
- EMGALITY$22,471
- NURTEC ODT$20,982
- ZAVZPRET$19,124
- Symbravo$18,759
- REYVOW$6,300
- Inspire$810
- Inspire Upper Airway Stimulation System$251
- remede System$136
- AIMOVIG$125
- VYALEV$117
How this compares
$793,052 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 13 | $276,618 |
| UbrelvyUbrogepant | 99 | $143,098 |
| QuliptaAtogepant | 75 | $88,489 |
| Nurtec OdtRimegepant Sulfate | 47 | $68,431 |
| Emgality PenGalcanezumab-Gnlm | 36 | $49,152 |
| XcopriCenobamate | 16 | $27,945 |
| BriviactBrivaracetam | 16 | $27,279 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $16,978 |
| NeuproRotigotine | 11 | $11,840 |
| Memantine Hcl | 167 | $9,883 |
| Rasagiline Mesylate | 35 | $9,245 |
| ReyvowLasmiditan Succinate | 11 | $8,441 |
| Lacosamide | 44 | $4,331 |
| Gabapentin | 212 | $4,006 |
| Entacapone | 18 | $3,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $261,696 | $231,587174 claims |
| PfizerNurtec Odt | $19,359 | $68,43147 claims |
| SK Life Science, Inc.Xcopri | $76 | $27,94516 claims |
| Lilly USA, LLCReyvow | $39,272 | $8,44111 claims |
| Upsher-smith Laboratories LLCTopiramate | $21 | $1,00155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Fort Wayne
- Ajay GuptaFort Wayne$2.5M
- James StevensFort Wayne$1.5M
- Marlene BultemeyerFort Wayne$525K
- Paul LaterFort Wayne$132K
- Christopher VachonFort Wayne$114K
- Thomas BanasFort Wayne$91K
- Fen Lei ChangFort Wayne$47K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.